Last reviewed · How we verify
danshen dripping pill
danshen dripping pill is a Herbal preparation / Traditional Chinese Medicine Small molecule drug developed by West China Hospital. It is currently FDA-approved for Angina pectoris, Myocardial infarction prevention, Coronary artery disease. Also known as: compound danshen dripping pill.
Danshen dripping pill improves blood circulation and reduces blood stasis by promoting vasodilation and inhibiting platelet aggregation.
Danshen dripping pill, also known as T89, has been studied in clinical trials for conditions such as angina pectoris, coronary arterial disease, and microvascular angina. The exact mechanism of action of danshen dripping pill is not specified in the provided facts, but it has been used in various studies, including a Phase III trial for stable angina prevention and treatment.
At a glance
| Generic name | danshen dripping pill |
|---|---|
| Also known as | compound danshen dripping pill |
| Sponsor | West China Hospital |
| Drug class | Herbal preparation / Traditional Chinese Medicine |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
The herbal formulation contains active compounds from Salvia miltiorrhiza (danshen) that enhance microcirculation, reduce blood viscosity, and prevent thrombotic events. It works through multiple pathways including antiplatelet effects, anticoagulation, and improvement of myocardial perfusion, making it useful in cardiovascular conditions characterized by blood stasis.
Approved indications
- Angina pectoris
- Myocardial infarction prevention
- Coronary artery disease
Common side effects
- Bleeding or bruising
- Gastrointestinal upset
- Allergic reactions
Key clinical trials
- Pre-trial of Clinical Trial of Traditional Chinese Medicine Treatment for Elderly Patients With Coronary Heart Disease Who Are Still Symptomatic After Optimal Medical Treatment (PHASE4)
- Compound Danshen Dripping Pill for Diabetic Microvascular Angina (PHASE4)
- Microvascular Angina Intervention With Compound Danshen Dripping Pill (MAIDS) (PHASE4)
- Effect of Compound Danshen Dripping Pills on Diabetic Patients With Coronary Microcirculation Disturbance (NA)
- Study of Compound Danshen Dripping Pills to Treat Acute Mountain Sickness (PHASE1, PHASE2)
- Phase III Study of Compound Danshen Dripping Pills to Treat Diabetic Retinopathy (PHASE3)
- Phase III Trial of Dantonic® (T89) Capsule to Prevent and Treat Stable Angina (PHASE3)
- Dose-Escalate Study to Investigate the Safety and Tolerability of T89 in Japanese (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- danshen dripping pill CI brief — competitive landscape report
- danshen dripping pill updates RSS · CI watch RSS
- West China Hospital portfolio CI
Frequently asked questions about danshen dripping pill
What is danshen dripping pill?
How does danshen dripping pill work?
What is danshen dripping pill used for?
Who makes danshen dripping pill?
Is danshen dripping pill also known as anything else?
What drug class is danshen dripping pill in?
What development phase is danshen dripping pill in?
What are the side effects of danshen dripping pill?
Related
- Drug class: All Herbal preparation / Traditional Chinese Medicine drugs
- Manufacturer: West China Hospital — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Angina pectoris
- Indication: Drugs for Myocardial infarction prevention
- Indication: Drugs for Coronary artery disease
- Also known as: compound danshen dripping pill
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing